Tenon(R) Medical Announces Full Commercial Launch of the SImmetry(R)+ SI Joint Fusion 3D Printed Lateral Screw Following Successful Alpha Launch
The limited Alpha launch generated approximately $1.2 million in preliminary, unaudited incremental revenue before broader commercialization.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenon Medical (TNON) launched its SImmetry+ titanium 3D-printed lateral screw commercially after completing a limited Alpha launch with physicians. The Alpha launch generated approximately $1.2 million in incremental revenue from late Q4 2025 through Q3 2026. That figure is preliminary and unaudited and is not necessarily indicative of future results.
SImmetry+ is a minimally invasive system for fusing the sacroiliac joint, which connects the pelvis and lower spine. Tenon added two implant sizes following input from Alpha users and newly trained surgeons. The company plans to expand instrument set inventory as needed to support anticipated demand and expects additional product launches in the coming quarters. Tenon acquired SImmetry+ in August 2025; its portfolio also includes the Catamaran SI Joint Fusion System.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointAlpha launch generated approximately $1.2 million in preliminary, unaudited incremental revenue from late Q4 2025 through Q3 2026. 66% of market cap
- Minor pointSImmetry+ lateral screw reached full commercial launch following completion of the limited Alpha launch.
- Minor point. Forward-looking: it has not happened yet and may not happen.Instrument set inventory expansion is planned as needed to support anticipated SImmetry+ demand.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional product launches are expected by Tenon in the coming quarters.
Negative
- None.
Details
Market Reaction – TNON
On Sep 30, the day this news came out, the latest delayed price for TNON is 1.12% above the previous close. The latest delayed price is $2.76. Relative volume is above average at 1.7x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Incremental Alpha launch revenue
- Approximately $1.2 million
- Late Q4 2025 through Q3 2026; preliminary and unaudited
- Additional implant sizes
- 2
- Added to the SImmetry+ portfolio
Key Terms
decortication medical
arthrodesis medical
sacroiliac medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS GATOS, CA / ACCESS Newswire / September 30, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients with sacro-pelvic disorders, today announced the full commercial launch of its new titanium 3D- printed lateral screw as part of the SImmetry+ SI Joint Fusion System following the successful completion of the implant's Alpha launch. The limited Alpha launch, involving existing SImmetry users and new physicians, generated approximately
Physician feedback from the Alpha launch was positive, with users highlighting the system's new screw design along with the system's ability to decorticate the joint prior to implantation, a step intended to strengthen joint fusion. SImmetry+ is a novel, minimally invasive, lateral and posterior oblique-access SI joint fusion system featuring new 3D-printed titanium implants and proprietary instrumentation. The System is built on established orthopedic principles, including joint decortication, bone graft delivery, and fixation, to achieve fusion of the sacroiliac joint in an efficient manner.
In response to input from Alpha users and newly trained surgeons preparing for their first cases, Tenon has expanded the SImmetry+ portfolio with two additional implant sizes, broadening the range of patient anatomies the system can address.
"We are very pleased with the early performance of the SImmetry+ SI Joint Fusion System and the strong feedback we've received from physician users," said Steven M. Foster, President and CEO of Tenon Medical. "We believe that this milestone supports the strategic rationale behind our acquisition of SImmetry+ in August 2025. Early case volume and revenue generated during the Alpha launch support our view that this platform can be a meaningful growth driver as we move into full commercial launch. Our re-engineered SImmetry+ screw is the first component of a next-generation lateral SI joint fusion system, and the first of several product launches we expect in the coming quarters, each designed to further improve patient outcomes and ease of use."
The choice of surgical approach to the SI joint is typically driven by physician training and experience. Tenon is the only company we know of offering multiple SI joint fusion approaches tailored to user preference: lateral and posterior oblique approaches with the SImmetry+ System, and an inferior-posterior approach with the Catamaran® SI Joint Fusion System. Both platforms are designed to provide immediate fixation, with long-term fusion as the goal. This breadth is intended to allow Tenon to serve a wider range of physicians and expand its reach across the SI joint fusion market.
"The goal of SI joint fusion is to stabilize the joint by reducing the micromotion that causes pain," said Ali Araghi, D.O., orthopedic spine surgeon at The CORE Institute in Phoenix, Arizona. "Achieving a true, long-term fusion of the SI joint can be a key component of favorable patient outcomes. The SImmetry+ System, with its unique 3D-printed implants designed for fixation and stability, allows me to treat the SI joint using principles consistent with traditional orthopedic fusion. I found the instrumentation and implants to be very effective and simple to use in these initial Alpha cases, and I look forward to continued advancements that further improve long-term outcomes and satisfaction for my SI joint patients."
The SImmetry+ and Catamaran® SI Joint Fusion Systems form the cornerstone of Tenon's growing portfolio of advanced technologies. The Company believes that together, they give Tenon a unique position in the market: three minimally invasive surgical approaches, each designed with the goal of achieving true arthrodesis, and supported by clinical evidence from the published prospective MAINSAIL™ and EVoluSIon™ studies. This differentiated portfolio allows physicians to tailor treatment to each patient, and, in the Company's view, positions Tenon to capture a broader share of the SI joint fusion market.
(1) This figure is preliminary and unaudited, is not necessarily indicative of future results.
About Tenon Medical, Inc.
Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon has been focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.
For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM is also a trademark of Tenon Medical, Inc.
Safe Harbor
This press release contains "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking statements often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements include, but are not limited to, statements regarding the anticipated commercial performance, adoption and demand for the SImmetry+ system; the timing of deployment of additional instrument sets; the development and timing of the next-generation lateral SI joint fusion system and future product launches; the SImmetry+ platform as a growth driver; the expected benefits of the Company's acquisition of SiVantage, Inc. and SIMPL Medical, LLC; the Company's market position and ability to expand market share; and anticipated clinical outcomes. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. Readers are cautioned not to place undue reliance on these forward-looking statements. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated from time to time in Tenon's Form 10-Q filings and in Tenon's other public filings on file with the SEC at www.sec.gov, particularly the information contained in the sections entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise, except as required by applicable law.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
SOURCE: Tenon Medical
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did Tenon Medical's SImmetry+ Alpha launch generate?
The SImmetry+ Alpha launch generated approximately $1.2 million in incremental revenue from late Q4 2025 through Q3 2026. The figure is preliminary and unaudited and is not necessarily indicative of future results.